Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors

References

• Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853–12. doi:10.1016/S0140-6736(17)31601-X.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356. doi:10.1056/NEJMoa1709684.
   PubMed Web of Science ®Google Scholar
• Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, Holland-Letz T, Umansky L, Beckhove P, Sucker A, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res. 2015;21(24):5453–5459. doi:10.1158/1078-0432.CCR-15-0676.
   PubMed Web of Science ®Google Scholar
• Rosner S, Kwong E, Shoushtari AN, Friedman CF, Betof AS, Brady MS, Coit DG, Callahan MK, Wolchok JD, Chapman PB, et al. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer Med. 2018;7(3):690–697. doi:10.1002/cam4.1356.
   PubMed Web of Science ®Google Scholar
• Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 2016;22(22):5487–5496. doi:10.1158/1078-0432.CCR-16-0127.
   PubMed Web of Science ®Google Scholar
• Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, Roy S, Eggermont AM, Routier E, Robert C. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol. 2013;24(6):1697–1703. doi:10.1093/annonc/mdt027.
   PubMed Web of Science ®Google Scholar
• Feldbausch F. The occurrence of eosinophilic leukocytes in tumours. Archiv Pathologische Anatomie Physiologie Klinische Medicin. 1900;161:1–18.
   Google Scholar
• Simon SCS, Utikal J, Umansky V. Opposing roles of eosinophils in cancer. Cancer Immunol Immunother. 2019;68(5):823–833. doi:10.1007/s00262-018-2255-4.
   PubMed Web of Science ®Google Scholar
• Dorta RG, Landman G, Kowalski LP, Lauris JR, Latorre MR, Oliveira DT. Tumour-associated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas. Histopathology. 2002;41(2):152–157. doi:10.1046/j1365-2559.2002.01437.x.
   PubMed Web of Science ®Google Scholar
• Prizment AE, Vierkant RA, Smyrk TC, Tillmans LS, Lee JJ, Sriramarao P, Nelson HH, Lynch CF, Thibodeau SN, Church TR, et al. Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Women’s Health study. Mod Pathol. 2016;29(5):516–527. doi:10.1038/modpathol.2016.42.
   PubMed Web of Science ®Google Scholar
• Steel JL, Kim KH, Dew MA, Unruh ML, Antoni MH, Olek MC, Geller DA, Carr BI, Butterfield LH, Gamblin TC. Cancer-related symptom clusters, eosinophils, and survival in hepatobiliary cancer: an exploratory study. J Pain Symptom Manage. 2010;39(5):859–871. doi:10.1016/j.jpainsymman.2009.09.019.
   PubMed Web of Science ®Google Scholar
• Oliveira DT, Biassi TP, Faustino SE, Carvalho AL, Landman G, Kowalski LP. Eosinophils may predict occult lymph node metastasis in early oral cancer. Clin Oral Investig. 2012;16(6):1523–1528. doi:10.1007/s00784-011-0651-7.
   PubMed Web of Science ®Google Scholar
• vanDriel WJ, Hogendoorn PCW, Jansen FW, Zwinderman AH, Trimbos JP, Fleuren GJ. Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for ex less effective immune response. Hum Pathol. 1996;27(9):904–911. doi:10.1016/s0046-8177(96)90216-6.
   PubMed Web of Science ®Google Scholar
• Huland E, Huland H. Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells. J Cancer Res Clin Oncol. 1992;118:463–467. doi:10.1007/BF01629431.
   PubMed Web of Science ®Google Scholar
• Sosman JA, Bartemes K, Offord KP, Kita H, Fisher SG, Kefer C, Ellis TA, Fisher RI, Higgins TJ, Gerald GJ. Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. Clin Cancer Res. 1995;1:805–812.
   PubMed Web of Science ®Google Scholar
• McNeel D, Gardner T, Higano C, Kantoff P, Small E, Wener M, Sims R, DeVries T, Sheikh N, Dreicer R. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T. Cancer Immunol Res. 2014;2(10):988–999. doi:10.1158/2326-6066.CIR-14-0073.
   PubMed Web of Science ®Google Scholar
• Tanizaki J, Haratani K, Hayashi H, Chiba Y, Nakamura Y, Yonesaka K, Kudo K, Kaneda H, Hasegawa Y, Tanaka K, et al. Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab. J Thorac Oncol. 2018;13(1):97–105. doi:10.1016/j.jtho.2017.10.030.
   PubMed Web of Science ®Google Scholar
• Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hammerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nature Immunol. 2015;16(6):609–617. doi:10.1038/ni.3159.
   PubMed Web of Science ®Google Scholar
• Lucarini V, Ziccheddu G, Macchia I, La Sorsa V, Peschiaroli F, Buccione C, Sistigu A, Sanchez M, Andreone S, D’Urso MT, et al. IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. Oncoimmunology. 2017;6(6). doi:10.1080/2162402x.2017.1317420.
   PubMed Web of Science ®Google Scholar
• Hartnell A, Robinson DS, Kay AB, Wardlaw AJ. CD69 is expressed by human eosinophils activated in vivo in asthma and in vitro by cytokines. Immunology. 1993;80:281–286.
   PubMed Web of Science ®Google Scholar
• Kinker KG, Gibson AM, Bass SA, Day BP, Deng J, Medvedovic M, Figueroa JA, Hershey GK, Chen W. Overexpression of dimethylarginine dimethylaminohydrolase 1 attenuates airway inflammation in a mouse model of asthma. PLoS One. 2014;9(1):e85148. doi:10.1371/journal.pone.0085148.
   PubMed Web of Science ®Google Scholar
• Matsuo K, Nagakubo D, Komori Y, Fujisato S, Takeda N, Kitamatsu M, Nishiwaki K, Quan YS, Kamiyama F, Oiso N, et al. CCR4 is critically involved in skin allergic inflammation of BALB/c mice. J Invest Dermatol. 2018;138(8):1764–1773. doi:10.1016/j.jid.2018.02.027.
   PubMed Web of Science ®Google Scholar
• Oh J, Malter JS. Pin1-FADD interactions regulate Fas-mediated apoptosis in activated eosinophils. J Immunol. 2013;190(10):4937–4945. doi:10.4049/jimmunol.1202646.
   PubMed Web of Science ®Google Scholar
• Kanzaki M, Shibagaki N, Hatsushika K, Mitsui H, Inozume T, Okamoto A, Dobashi Y, Ogawa H, Shimada S, Nakao A. Human eosinophils have an intact Smad signaling pathway leading to a major transforming growth factor-beta target gene expression. Int Arch Allergy Immunol. 2007;142(4):309–317. doi:10.1159/000097500.
   PubMed Web of Science ®Google Scholar
• Nagase H, Okugawa S, Ota Y, Yamaguchi M, Tomizawa H, Matsushima K, Ohta K, Yamamoto K, Hirai K. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol. 2003;171(8):3977–3982. doi:10.4049/jimmunol.171.8.3977.
   PubMed Web of Science ®Google Scholar
• Becher B, Schlitzer A, Chen J, Mair F, Sumatoh HR, Teng KW, Low D, Ruedl C, Riccardi-Castagnoli P, Poidinger M, et al. High-dimensional analysis of the murine myeloid cell system. Nat Immunol. 2014;15(12):1181–1189. doi:10.1038/ni.3006.
   PubMed Web of Science ®Google Scholar
• Douglas IS, Leff AR, Sperling AI. CD4+ T cell and eosinophil adhesion is mediated by specific ICAM-3 ligation and results in eosinophil activation. J Immunol. 2000;164(6):3385–3391. doi:10.4049/jimmunol.164.6.3385.
   PubMed Web of Science ®Google Scholar
• Moreira A, Leisgang W, Schuler G, Heinzerling L. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy. Immunotherapy. 2017;9(2):115–121. doi:10.2217/imt-2016-0138.
   PubMed Web of Science ®Google Scholar
• Furbert-Harris P, Parish-Gause D, Laniyan I, Hunter KA, Okomo-Awich J, Vaughn TR, Forrest KC, Howland C, Abdelnaby A, Oredipe OA. Inhibition of prostate cancer cell growth by activated eosinophils. Prostate. 2003;57(2):165–175. doi:10.1002/pros.10286.
   PubMed Web of Science ®Google Scholar
• Rosas M, Dijkers PF, Lindemans CL, Lammers JW, Koenderman L, Coffer PJ. IL-5-mediated eosinophil survival requires inhibition of GSK-3 and correlates with beta-catenin relocalization. J Leukoc Biol. 2006;80(1):186–195. doi:10.1189/jlb.1105636.
   Web of Science ®Google Scholar
• Yasukawa A, Hosoki K, Toda M, Miyake Y, Matsushima Y, Matsumoto T, Boveda-Ruiz D, Gil-Bernabe P, Nagao M, Sugimoto M, et al. Eosinophils promote epithelial to mesenchymal transition of bronchial epithelial cells. PLoS One. 2013;8(5):e64281. doi:10.1371/journal.pone.0064281.
   PubMed Web of Science ®Google Scholar
• Kagalwalla AF, Akhtar N, Woodruff SA, Rea BA, Masterson JC, Mukkada V, Parashette KR, Du J, Fillon S, Protheroe CA, et al. Eosinophilic esophagitis: epithelial mesenchymal transition contributes to esophageal remodeling and reverses with treatment. J Allergy Clin Immunol. 2012;129(5):1387–1396 e1387. doi:10.1016/j.jaci.2012.03.005.
   PubMed Web of Science ®Google Scholar
• Fernvik E, Lundahl J, Magnusson CG, Hallden G. The effect of in vitro activation and platelet interaction on the CD9 distribution and adhesion properties of human eosinophils. Inflamm Res. 1999;48(1):28–35. doi:10.1007/s000110050383.
   PubMed Web of Science ®Google Scholar
• Shah SA, Page CP, Pitchford SC. Platelet-eosinophil interactions as a potential therapeutic target in allergic inflammation and asthma. Front Med (Lausanne). 2017;4:129. doi:10.3389/fmed.2017.00129.
   PubMed Web of Science ®Google Scholar
• Plantureux L, Mege D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Impacts of cancer on platelet production, activation and education and mechanisms of cancer-associated thrombosis. Cancers (Basel). 2018;10(11). doi:10.3390/cancers10110441.
   PubMed Web of Science ®Google Scholar
• Ulfman LH, Kamp VM, van Aalst CW, Verhagen LP, Sanders ME, Reedquist KA, Buitenhuis M, Koenderman L. Homeostatic intracellular-free Ca2+ is permissive for Rap1-mediated constitutive activation of alpha4 integrins on eosinophils. J Immunol. 2008;180(8):5512–5519. doi:10.4049/jimmunol.180.8.5512.
   PubMed Web of Science ®Google Scholar
• Ulfman LH, Kuijper PH, van der Linden JA, Lammers JW, Zwaginga JJ, Koenderman L. Characterization of eosinophil adhesion to TNF-alpha-activated endothelium under flow conditions: alpha 4 integrins mediate initial attachment, and E-selectin mediates rolling. J Immunol. 1999;163:343–350.
   PubMed Web of Science ®Google Scholar
• Cormier SA, Taranova AG, Bedient C, Nguyen T, Protheroe C, Pero R, Dimina D, Ochkur SI, O’Neill K, Colbert D, et al. Pivotal advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J Leukoc Biol. 2006;79(6):1131–1139. doi:10.1189/jlb.0106027.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571. doi:10.1038/nature13954.
   PubMed Web of Science ®Google Scholar
• Reichman H, Itan M, Rozenberg P, Yarmolovski T, Brazowski E, Varol C, Gluck N, Shapira S, Arber N, Qimron U, et al. Activated eosinophils exert antitumorigenic activities in colorectal cancer. Cancer Immunol Res. 2019;7(3):388–400. doi:10.1158/2326-6066.CIR-18-0494.
   PubMed Web of Science ®Google Scholar
• Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer. 2014;2:3. doi:10.1186/2051-1426-2-3.
   PubMedGoogle Scholar
• Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, Hernandez IM, Gutierrez C, Lopez-Berestein G, Camacho LH. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer. 2006;106(11):2437–2444. doi:10.1002/cncr.21854.
   PubMed Web of Science ®Google Scholar
• Munitz A, Bachelet I, Eliashar R, Moretta A, Moretta L, Levi-Schaffer F. The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils. Blood. 2006;107(5):1996–2003. doi:10.1182/blood-2005-07-2926.
   PubMed Web of Science ®Google Scholar
• Lim KG, Wan HC, Bozza PT, Resnick MB, Wong DT, Cruikshank WW, Kornfeld H, Center DM, Weller PF. Human eosinophils elaborate the lymphocyte chemoattractants. IL-16 (lymphocyte chemoattractant factor) and RANTES. J Immunol. 1996;156:2566–2570.
   PubMed Web of Science ®Google Scholar
• Rand TH, Cruikshank WW, Center DM, Weller PF. CD4-mediated stimulation of human eosinophils: lymphocyte chemoattractant factor and other CD4-binding ligands elicit eosinophil migration. J Exp Med. 1991;173(6):1521–1528. doi:10.1084/jem.173.6.1521.
   PubMed Web of Science ®Google Scholar
• Ferland C, Flamand N, Davoine F, Chakir J, Laviolette M. IL-16 activates plasminogen-plasmin system and promotes human eosinophil migration into extracellular matrix via CCR3-chemokine-mediated signaling and by modulating CD4 eosinophil expression. J Immunol. 2004;173(7):4417–4424. doi:10.4049/jimmunol.173.7.4417.
   PubMed Web of Science ®Google Scholar
• Bandeira-Melo C, Sugiyama K, Woods LJ, Phoofolo M, Center DM, Cruikshank WW, Weller PF. IL-16 promotes leukotriene C(4) and IL-4 release from human eosinophils via CD4- and autocrine CCR3-chemokine-mediated signaling. J Immunol. 2002;168(9):4756–4763. doi:10.4049/jimmunol.168.9.4756.
   PubMed Web of Science ®Google Scholar
• Wu KG, Li TH, Chen CJ, Cheng HI, Wang TY. Correlations of serum Interleukin-16, total IgE, eosinophil cationic protein and total eosinophil counts with disease activity in children with atopic dermatitis. Int J Immunopathol Pharmacol. 2011;24(1):15–23. doi:10.1177/039463201102400103.
   PubMed Web of Science ®Google Scholar
• Gonzalo JA, Lloyd CM, Wen D, Albar JP, Wells TN, Proudfoot A, Martinez AC, Dorf M, Bjerke T, Coyle AJ, et al. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med. 1998;188(1):157–167. doi:10.1084/jem.188.1.157.
   PubMed Web of Science ®Google Scholar
• Gaga M, Ong YE, Benyahia F, Aizen M, Barkans J, Kay AB. Skin reactivity and local cell recruitment in human atopic and nonatopic subjects by CCL2/MCP-1 and CCL3/MIP-1alpha. Allergy. 2008;63(6):703–711. doi:10.1111/j.1398-9995.2007.01578.x.
   PubMed Web of Science ®Google Scholar
• Radman M, Hassanshahi G, Vazirinejad R, Arababadi MK, Karimabad MN, Khorramdelazad H, Rafatpanah H, Iranmanesh F, Hakimizadeh E, Ahmadi Z. Serum levels of the CC chemokines CCL2, CCL5, and CCL11 in food allergic children with different clinical manifestations. Inflammation. 2013;36(3):561–566. doi:10.1007/s10753-012-9577-8.
   PubMed Web of Science ®Google Scholar
• Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, Patterson JW, Slingluff CL Jr. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012;72(5):1070–1080. doi:10.1158/0008-5472.CAN-11-3218.
   PubMed Web of Science ®Google Scholar
• Butterfield JH, Kephart GM, Banks PM, Gleich GJ. Extracellular deposition of eosinophil granule major basic protein in lymph nodes of patients with Hodgkin’s disease. Blood. 1986;68:1250–1256. doi:10.1182/blood.V68.6.1250.1250.
   PubMed Web of Science ®Google Scholar
• Kubo H, Loegering DA, Adolphson CR, Gleich GJ. Cytotoxic properties of eosinophil granule major basic protein for tumor cells. Int Arch Allergy Immunol. 1999;118(2–4):426–428. doi:10.1159/000024154.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007.
   PubMed Web of Science ®Google Scholar
• Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417–425. doi:10.1016/j.cels.2015.12.004.
   PubMed Web of Science ®Google Scholar
• Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, Haw R, Jassal B, Korninger F, May B, et al. The reactome pathway knowledgebase. Nucleic Acids Res. 2018;46(D1):D649–D655. doi:10.1093/nar/gkx1132.
   PubMed Web of Science ®Google Scholar